The Signs Your Immune System Is Slowing Down With Age
How immunity changes with age
Immune function doesn't stay constant across life — it changes in predictable, well-documented ways with age, and understanding this is part of why several vaccines have specific older-adult recommendations rather than a one-size-fits-all schedule.
What Actually Changes
A comprehensive review of immune ageing — a process termed immunosenescence — describes a complex set of changes: declining production of new immune cells, a less diverse pool of cells available to respond to novel threats, and dysregulated inflammatory signalling (the immune system's alarm signals firing too often, too weakly, or at the wrong times), all combining to reduce both the ability to fight off new infections and the strength of the response generated by vaccination itself[4]. This is why older adults are simultaneously at higher risk from many infections and get somewhat less robust protection from a standard vaccine dose — a frustrating combination that public health has specifically addressed with tailored formulations.
What You Might Notice
Immunosenescence is usually described in lab terms, but it can show up in everyday life too. None of these signs prove anything on their own — there are plenty of other explanations for each — but they're worth noticing, and worth mentioning to a doctor if several appear together:
Infections that last longer or come back more often than they used to — a cold that lingers for two weeks instead of a few days, or repeated infections within a single season.
Slower wound healing — cuts, bruises, or minor injuries taking noticeably longer to close up than they did in earlier years.
A weaker response to vaccines you've had before — for example, needing a booster sooner than expected, or a doctor noting that a vaccine's protection seems to be fading faster than typical.
How Vaccine Design Has Adapted
Several vaccines specifically formulated or dosed for older adults exist precisely to compensate for this reduced responsiveness — higher-dose flu vaccines for those over 65, and adjuvanted formulations (containing an ingredient that boosts the immune response to the vaccine) like the modern shingles vaccine. In a large randomised placebo-controlled trial across 18 countries with over 15,000 participants, the adjuvanted recombinant shingles vaccine substantially reduced the risk of shingles across all age groups studied, including those 70 and older — a population where older, non-adjuvanted shingles vaccines had shown meaningfully weaker efficacy[5]. This is a direct, practical example of vaccine science responding to the immunosenescence problem with a more effective solution, not just a reformulated older product.
Section takeaway
Immune function declines with age in measurable, well-characterised ways, and can show up as slower-healing wounds, infections that linger or recur, or a weaker response to vaccines you've had before. That's precisely why several vaccines have specific older-adult formulations or recommendations — not because older adults are lower priority, but because they need a version of the vaccine specifically engineered to work despite reduced immune responsiveness.